Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05411627
Other study ID # 2022P000682
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date December 15, 2023

Study information

Verified date February 2024
Source Spaulding Rehabilitation Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study of the efficacy, safety, and tolerability of shockwave therapy for the treatment of spasticity in Hereditary Spastic Paraplegia.


Description:

This is a pilot study investigating the efficacy, safety, and tolerability of Extracorporeal Shockwave Therapy (ESWT) for the treatment of lower-extremity spasticity in the setting of Hereditary Spastic Paraplegia (HSP). 8 participants will be treated with shockwave therapy targeting sites of maximal spasticity in the lower extremities for 3 sessions at a rate of once per week. Participants will fill out baseline questionnaires assessing their overall wellbeing and function prior to treatment session 1, and will complete follow-up questionnaires at visit 2, visit 3, a phone call within 7 days of visit 3, and 8 weeks after initial visit. Total time enrolled in the study will be 8 weeks


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 15, 2023
Est. primary completion date October 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Over the age of 18 2. Diagnosis of genetically-confirmed HSP 3. Score of 2, 3 or 4 on the PLSFRS walking question 4. 30 days stable dosages of oral spasticity medications prior to screening and throughout study participation 5. Able to come to site for treatment sessions 6. Able to understand all study procedures Exclusion Criteria: 1. Diagnosis of any other neurological disorder that may impact gait 2. Lower motor neuron (LMN) disease or combined UMN and LMN 3. Non-ambulatory or requiring two-person assistance for any functional ambulation on most days 4. Less than 3 months of symptoms 5. Have received SWT within the past 3 months 6. Prior botulinum toxin injection within 3 months or planning to receive botulinum toxin injections during the study participation for spasticity management 7. Presence of an intra-thecal baclofen pump 8. Women who are pregnant. This is due to the fact that pregnancy will reduce participants activity after the treatment and the safety concerns related to shockwave treatment. 9. Patients with neuropathy affecting sensation to pain 10. Patients with a known underlying cardiac disease that could be affected by shockwave therapy 11. Concomitant intake of another clinical trial or other off-label experimental treatments that might influence study outcomes 12. Presence of unstable psychiatric disease, cognitive impairments, or dementia impairing study participation 13. Presence of other chronic neurological diseases such as Alzheimer's Parkinson's, stroke, or multiple sclerosis 14. Personal history of narcotic overuse for chronic pain or substance abuse or dependence 15. Contraindications for ESWT, including local skin breakdown, infection, malignancy or other soft tissue pathology at sites of planned treatment.

Study Design


Intervention

Device:
Shockwave Therapy
Participants will receive shockwave therapy once per week for three weeks.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Spaulding Rehabilitation Hospital Massachusetts General Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical Rating Scale for Pain A rating of pain from 0 (none) to 10 (worst) 0-8 weeks; assessed at baseline visit, 1, 2, 3, and 8 weeks
Primary Primary Lateral Sclerosis Functional Rating Scale (PLSFRS) The score of the rating scale ranges from 0-68, where 68 is a person who is completely asymptomatic. 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Neurological Quality of Life (Neuro-QoL) Questionnaire: Fatigue Short Form The score of this questionnaire ranges from 8 (least fatigue) to 40 (most fatigue) 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Foot and Ankle Ability Measure (FAAM) Questionnaire: Activities of Daily Living Subscale The score of this questionnaire ranges from 0 (maximally symptomatic in activities of daily living) to 84 (asymptomatic in activities of daily living). 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Global Rate of Change (GROC) Questionnaire The score ranges from -7 (maximally negative change) to +7 (maximally positive change) 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Neurological Quality of Life (Neuro-QoL) Questionnaire: Lower Extremity Function - Mobility Short Form The score of this questionnaire ranges from 8 (minimal lower extremity function) to 40 (maximal lower extremity function) 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Neurological Quality of Life (Neuro-QoL) Questionnaire: Positive Affect and Wellbeing Short Form The score of this questionnaire ranges from 9 (minimal wellbeing) to 45 (maximal wellbeing) 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Neurological Quality of Life (Neuro-QoL) Questionnaire: Satisfaction with Social Roles and Activities Short Form The score of this questionnaire ranges from 8 (minimal satisfaction) to 40 (maximal satisfaction) 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Foot and Ankle Ability Measure (FAAM) Questionnaire: Sports Subscale The score of this questionnaire ranges from 0 (maximally symptomatic in sports activities) to 32 (asymptomatic in sports activities) 0-8 weeks; assessed at baseline visit, 1, 3, and 8 weeks
Primary Ten-Meter Walk Test Participants will be asked to walk ten meters 2x at their self-selected walking speed and 2x at their fast walking speed. Time taken to complete walks will be measured. 0-3 weeks; assessed at baseline visit, 1, 2, and 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT05373082 - Identification of Modifying Factors in Hereditary Spastic Paraplegia
Recruiting NCT03981276 - Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
Terminated NCT02859428 - Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
Completed NCT03104088 - Studying Cognition in SPG4
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Completed NCT02604186 - Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Phase 2/Phase 3
Completed NCT04912609 - Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)
Recruiting NCT03206190 - The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4 N/A
Completed NCT03627416 - Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy N/A
Recruiting NCT04875416 - Phenotype, Genotype and Biomarkers 2
Completed NCT03961906 - Physiotherapy in Hereditary Spastic Paraplegia Phase 2
Completed NCT05767268 - Assessment of the Psychophysical State During Rehabilitation Treatment With Lokomat
Completed NCT02852278 - A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Completed NCT04180098 - Improving Gait Adaptability in Hereditary Spastic Paraplegia N/A
Completed NCT05613114 - Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia N/A
Completed NCT00023075 - Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis N/A
Recruiting NCT04712812 - Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
Recruiting NCT05354622 - Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Enrolling by invitation NCT02327845 - Phenotype, Genotype & Biomarkers in ALS and Related Disorders